Allogeneic vs. Autologous Stem Cell Therapy: From Basic Science to Clinical Applications
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2006
Special Issue Editors
Interests: mesenchymal stromal cells; extracellular vesicles; secretome; joint diseases; osteoarthritis; regenerative medicine
Special Issues, Collections and Topics in MDPI journals
Interests: regenerative medicine; placenta; amniotic membrane; mesenchymal stromal cells; secretome; immunomodulation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mesenchymal stromal cells (MSCs) have been the subject of several basic, pre-clinical, translational and clinical studies for a wide range of diseases, including neurological disorders, cardiac ischemia, diabetes, and bone and cartilage defects, among others. All these MSC-based studies have established that MSCs are safe, although their efficacy and mechanism of action have not been completely established, thus consequently slowing down the progression of clinical studies to phase 2 or 3. Among the still obscure areas that are under intense and active investigation, the variable outcomes of MSC therapy are crucial issues, with several issues identified as critical determinants for MSC response patterns. In light of this, MSC efficacy was shown to be influenced by many factors in both cell preparation and administration to patients, including study design, cell manufacturing techniques, dosing regimen and route of delivery. Moreover, the choice of both the pathology and the patients to be treated can be difficult, often due to conflicting scientific results or inadequate preclinical animal models. Thus, covering all these aspects of MSC-based therapeutic approaches and clinical outcomes, the benefits of allogeneic versus autologous therapy remain a highly debated topic in the MSC field. This Special Issue provides a platform to share cutting-edge research for all aspects of MSC-based regenerative therapy, from basic science to clinical studies, with particular emphasis on allogeneic, autologous and comparative settings.
Prof. Dr. Enrico Ragni
Dr. Antonietta Rosa Silini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesenchymal stromal cells
- regenerative medicine
- immune reaction
- transplant
- basic research
- preclinical studies
- clinical studies
- manufacturing processes
- patient selection
